
    
      Compare the efficacy and safety of viramidine 600 mg BID versus ribavirin 1000/1200 mg/day,
      both drugs administered in combination with pegylated interferon alfa-2b to treatment-naive
      patients with chronic hepatitis C (CHC)
    
  